Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC) [abstract 901] - Burtness,B.A.; Li,Y.; Flood,W. (Proc Am Soc Clin Oncol, 2002)